<DOC>
	<DOCNO>NCT01108029</DOCNO>
	<brief_summary>Along cognitive psychobehavioural disorder , gait disorder represent major problem treatment advance Parkinson 's disease ( PD ) . PD consider hyperglutamatergic disease dopaminergic depletion induces hyperactivity subthalamic nucleus ( STN ) internal pallidum ( GPi ) , glutamatergic hyperactivity STN 's efferent pathway , i.e. , subthalamopallidal , subthalamonigral subthalamo-entopeduncular pathway ( project pedunculopontine nucleus ( PPN ) ) . Excess glutamate PPN also observe 6-OHDA rat model PD . Reduction glutamatergic hyperactivity within PPN via systemic intra-peduncular administration glutamate antagonists improve akinesia drug-induced murine primate model PD , via NMDA AMPA receptor . High dos memantine ( 10 mg/kg ) improve locomotion reserpine- alpha-methyl-p-tyrosine-treated rat . In human , PPN may play key role gait , posture control , axial rigidity attention . It also involve gate sensory information involve startle reflex , study via prepulse inhibition ( PPI ) blink reflex . At present , two uncompetitive NMDA receptor antagonist approve use human : amantadine memantine . Reviews recent literature drug identify publish study specifically severe gait attention disorder PD . Memantine partial blocker open NMDA channel . The value memantine relate fact decrease excessive glutamatergic transmission lower synaptic noise due excessive activation NMDA receptor . In double-blind study , investigator shall seek demonstrate presence absence effect memantine gait attention disorder . In order study interaction glutamatergic hyperactivity dopaminergic system , investigator shall study phenomena absence L-dopa follow acute administration latter . Twenty eight volunteer , non-demented , late-stage PD patient display severe gait disorder receive memantine ( 20 mg/day ) placebo 3 month . The investigator expect see reduction gait attention disorder , together improvement blink reflex PPI memantine . This pilot study could subsequently turn double-blind , placebo-controlled multicenter study .</brief_summary>
	<brief_title>Study Memantine Gait Disorders And Attention Deficit In Parkinson 's Disease</brief_title>
	<detailed_description>Overall study duration : 2 year . Planned inclusion period : 12 month . Study duration individual patient : 4 month 2 week ( 2 week screen randomization , 3 month double-blind treatment 4-week wash-out period ) . Primary objective ( V1 V4 ) : To assess efficacy memantine treatment severe gait disorder assess stride length gait analysis optoelectronic system ( VICON® ) patient advance Parkinson 's disease subthalamic stimulation Additional Efficacy Endpoints ( V1 V4 ) : - Kinematic Kinetic parameter ( stride length , stride time , velocity , cadence ) gait initiation stabilize gait use optoelectronic system ( VICON® ) - Gait motor symptom : `` Freezing Of Gait trajectory '' , UPDRS score ( part III ) , dyskinesia rating scale , - Axial rigidity : measure passive flexion isokinetic dynamometer ( Cybex 6000 ) - Axial strength : measure active flexion isokinetic dynamometer ( Cybex 6000 ) - Attention : simple complex reaction time - The inhibition presynaptic dopamine transporter memantine assess mean DAT density bilateral striatum ( putamen caudate nucleus ) use [ 99mTc ] TRODAT-1 SPECT Safety Tolerability Endpoints ( V1 , V2 , V3 V4 ) : - Drowsiness : Epworth Parkinson 's disease Sleep Scales - Apathy Lille Apathy Rating Scale - Depression : MADRS , - Pharmacokinetic property memantine analyze low plasmatic concentration memantine morning intake blind treatment 7:00 h , steady state 3 month ( blind secondary analyse ) . - Safety : Recording serious non serious adverse event report patient , electrocardiogram , blood pressure biological analyzes ( blood count , ionogram , urea , creatinemia , transaminase , alkaline phosphatase , bilirubinemia , gamma GT , magnesium ) - Tolerability Number subject ( % ) discontinue study Number subject ( % ) discontinue study due AEs Safety Measures AE incidence Safety laboratory value Vital sign Blood pressure monitor ECG Physical neurological examination Study Design Monocentric study : 12-week double blind , placebo-controlled phase . After find eligible participate study , subject allocate 1:1 ratio one follow two treatment group base randomization scheme block stratify : one memantine 1. st week : 5 mg per day morning 2. nd week : 10 mg per day morning 3. rd week : 15 mg per day morning 4. th week : 20 mg per day morning one placebo 3 month memantine Schedule : 5 visit : screening ( V0 ) , randomization ( V1 , 15 day V0 ) , ( V2 ) visit 1 month , ( V3 ) visit 2 month termination ( V4 , 3 month randomization ) Patients : 28 subject Parkinson 's disease duration 5 year , without dementia ( Mattis Dementia Rating Scale ≥ 130 , MMSE ≥ 27 DSM IV ) , without major depression ( MADRS &lt; 18 ) severe gait disorder include freeze gait ( define answer 2 3 3rd question autoquestionnaire Giladi : Do gait disorder impede daily living activity independence : answer : yes , moderately severely . But patient require physical assistance walk ) despite optimal dopaminergic treatment optimal stable subthalamic stimulation parameter . No additional therapy permit study . Centre : LILLE : Department Neurology , University Hospital Lille : Pr L. Defebvre , Pr K. Dujardin , Dr D. Devos , Pr Destee , Mme Delliaux . Dr A Kreisler , Dr C Simonin , Dr C. Moreau , Dr A. Delval Department Pharmacology , Faculté de Médecine , Lille II .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Nervous System Diseases</mesh_term>
	<mesh_term>Gait Disorders , Neurologic</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>Parkinson 's disease 5 year Subthalamic nucleus stimulation Gait disorder impede moderately severely activity daily live gait disorder include freeze gait able walk without physical assistance Dementia ( MMSE &lt; 27 et score de Mattis &lt; 130 ) Requiring dopatherapy modification Requiring subthalamic stimulation parameter adaptation Psychiatric disorder : hallucination , unstable thymic disorder , psychosis ) Cardiac disorder : dysrhythmia unstable arterial hypertension Unstable severe medical illness intolerance contraindication memantine</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Freezing Gait</keyword>
	<keyword>Memantine</keyword>
	<keyword>NMDA receptor</keyword>
	<keyword>glutamate</keyword>
	<keyword>No Dementia</keyword>
</DOC>